For more than 50 years, the methylation of mammalian actin at histidine 73 has been known to occur 1 . Despite the pervasiveness of His73 methylation, which we find is conserved in several model animals and plants, its function remains unclear and the enzyme that generates this modification is unknown. Here we identify SET domain protein 3 (SETD3) as the physiological actin His73 methyltransferase. Structural studies reveal that an extensive network of interactions clamps the actin peptide onto the surface of SETD3 to orient His73 correctly within the catalytic pocket and to facilitate methyl transfer. His73 methylation reduces the nucleotide-exchange rate on actin monomers and modestly accelerates the assembly of actin filaments. Mice that lack SETD3 show complete loss of actin His73 methylation in several tissues, and quantitative proteomics analysis shows that actin His73 methylation is the only detectable physiological substrate of SETD3. SETD3-deficient female mice have severely decreased litter sizes owing to primary maternal dystocia that is refractory to ecbolic induction agents. Furthermore, depletion of SETD3 impairs signal-induced contraction in primary human uterine smooth muscle cells. Together, our results identify a mammalian histidine methyltransferase and uncover a pivotal role for SETD3 and actin His73 methylation in the regulation of smooth muscle contractility. Our data also support the broader hypothesis that protein histidine methylation acts as a common regulatory mechanism.
H-SAM (S-adenosyl methionine) on total cytoplasmic extracts with wild-type or mutant SETD3. An approximately 42-kDa band was more prominent in reactions with wild-type SETD3 relative to the mutant (Fig. 1b) . A three-step fractionation protocol was used to partially purify the SETD3-dependent activity for mass spectrometry analysis (Extended Data Fig. 1d -g). The ten most abundant hits in the proteomic dataset with molecular weights close to the candidate substrate (Extended Data Fig. 1h and Supplementary Table 1 ) were expressed as recombinant proteins and directly tested as SETD3 substrates in vitro ( Fig. 1c ). Of these proteins and other potential substrates, only β-actin was methylated by SETD3 ( Fig. 1c and Extended Data Fig. 1i ). SETD6 and 10 additional active PKMTs do not methylate actin (Fig. 1d , e and Extended Data Fig. 1j ). In addition, SETD3 does not methylate the SETD6 substrate RelA 6 (Fig. 1d) . These data identify SETD3 as an enzyme that methylates actin in vitro.
To identify the specific actin residue(s) that are modified by SETD3, in vitro methylated actin was analysed by tandem mass spectrometry; deuterated SAM was used as the methyl donor to distinguish SETD3catalysed methylation from all other sources. Unexpectedly, no lysine methylation events on actin were observed (Extended Data Fig. 2 ). We therefore extended the analysis to search for methylation events at other residues (arginine, glutamine, cysteine and histidine) and unambiguously identified incorporation of a single deuterated methyl moiety at His73 of actin (Extended Data Fig. 3a-c) . Histidine methylation is known to exist on a limited number of proteins. The only known histidine methyltransferase is the yeast enzyme Hpm1p, which methylates Rpl3 (not actin) and bears no structural resemblance to SETD3 7, 8 . However, methylation of actin at His73 (actin-His73me) is a canonical modification present in mammals but not in yeast 1, 7, 9 . We identified His73me (or equivalent) on actin purified from 10 different model organisms, ranging from worms to plants to humans, that all have a SETD3 homologue, but not in Saccharomyces cerevisiae, which lacks SETD3 (Extended Data Fig. 4 ). Thus, actin-His73me is an evolutionarily conserved modification that is present in a broad range of multicellular eukaryotic organisms.
Mutation of actin His to Ala at position 73 (H73A) prevents methylation by SETD3 ( Fig. 2a ). Histidine can potentially be methylated on the nitrogen in position 1 (π, N1) or 3 (τ, N3) of the imidazole ring ( Fig. 2b) ; His(3-me) is the physiological modification that is found on endogenous actin. Methylation assays performed on actin peptides that spanned His73 (residues 66-80 of β-actin) and in which His73 was either unmethylated or methylated at the N1 or N3 position (Extended Data Fig. 3d ) showed that SETD3 methylated the unmodified peptide (k cat , 0.4 min −1 ) and the His73(1-me)-containing peptide (at a much slower rate), but not the His73(3-me)-containing peptide, indicating Letter reSeArCH that SETD3 catalyses methylation of His73 at the physiologically relevant N3 position ( Fig. 2c and Extended Data Fig. 3e-g) .
To gain insight into the molecular basis of how SETD3 methylates a histidine substrate, we co-crystallized SETD3 with an actin peptide (residues 66-80) that contains His73 in the presence of S-adenosyl-lhomocysteine (SAH). We obtained three highly similar crystal forms, focusing on the highest resolution structure of 1.69 Å (Extended Data Table 1 ). SETD3 contains two lobes (SET and LSMT-like) forming a V-shaped cleft (Extended Data Fig. 5a ). The 15-residue actin peptide occupies an extended surface groove of the SET domain ( Fig. 2d) , with His73 inserted into the active-site channel positioned to meet SAH from the other end ( Fig. 2e ). From the viewpoint of the cofactor-binding pocket, the methyl-accepting His73 N3 atom is seen at the bottom of the channel (Extended Data Fig. 5b ). Structural superimposition of SETD3 and SETD6 5 reveals that for SETD3, the methyl donor group of SAM points towards and is within the distance of 1.8 Å of the target N3 atom of the imidazole ring ( Fig. 2f ). An intramolecular hydrogen bond between the main-chain carbonyl oxygen of Glu72 and the main-chain amide nitrogen of Ile75 bends the peptide substrate in a sharp turn at His73. This configuration allows His73 and Gly74 (the smallest residue) to enter deep into the channel and positions the target N3 atom in line with the methyl group and sulfur atom of SAM ( Fig. 2f and Extended Data Fig. 5c, d) ; a linear arrangement comprising the nucleophile, the methyl group and the leaving thioester group in the transition state is required for the S N 2 reaction mechanism used by SAM-dependent methyltransferases 10 .
All 15 residues of the actin peptide are bound in the structure ( Fig. 2d and Extended Data Fig. 5d ), with the SETD3-actin peptide interface consisting of an extensive network of charged/polar and hydrophobic interactions that involve both inter-and intramolecular contacts (Extended Data Fig. 5d -n). For example, Trp79 and Ile71 of actin each fit into hydrophobic pockets on the SETD3 surface ( Fig. 2g ). This long and ordered peptide-substrate recognition groove for SETD3 is unique compared to other SET domains 11 , suggesting that SETD3 would inefficiently accommodate substrates that diverge from actin. Structure-guided point mutations in actin that disrupt the hydrophobic interaction (I71A) or are predicted to interfere with proper positioning of His73 in the catalytic pocket (G74I) impair the ability of SETD3 to methylate actin-His73 and the double mutant (I71A/G74I) abolishes activity ( Fig. 3a) . Furthermore, although a W79E substitution is tolerated (Extended Data Fig. 5e ), SETD3 has no activity on actin I71A/ W79E double mutations (Fig. 3a) . These data highlight the sensitivity of SETD3 activity on actin to changes in the sequence that includes His73. Indeed, the 15-residue sequence spanning His73 is highly conserved among the six human actin isoforms 9,12 with the only difference being an Ile/Val variation at position 76 that does not affect SETD3 recognition (Extended Data Fig. 5g, o) . Accordingly, all actin isoforms are methylated by SETD3 in vitro ( Fig. 3b ). Finally, the putative SETD3 catalytic mutant is a conserved tyrosine (Tyr312) that participates in forming the active-site pocket (Extended Data Fig. 5d , i, p). This mutant has residual activity; however, mutation of additional conserved residues that are important for SAM binding abolished SETD3 activity ( Fig. 3c and Extended Data Fig. 5p ).
We next generated a state-specific actin-His73me antibody that selectively recognized His73(3-me) peptides (Extended Data Fig. 6a ). The majority of endogenous actin is marked by His73 methylation in HT1080 cancer cells and the depletion of endogenous SETD3 by two independent single-guide RNAs (sgRNAs) results in almost complete loss of this modification, as determined by western blotting and mass spectrometry ( Fig. 3d and Extended Data Fig. 6b ). We also observed complete loss of actin-His73me in a clonal HeLa cell line in which the SETD3 alleles were disrupted ( Fig. 3e and Extended Data Fig. 6c ). Furthermore, complementation of SETD3-depleted HT1080 Letter reSeArCH cells with CRISPR-resistant wild-type, but not with catalytically dead SETD3(NHY), reconstituted actin methylation at His73 ( Fig. 3f and Extended Data Fig. 6d ). To assess the physiological role of SETD3 in regulating actin His73 methylation, we obtained Setd3 +/− mice from the Canadian Mouse Mutant Repository 13 and generated Setd3 null homozygote mice (Setd3 −/− ) that are viable. Analysis of actin purified from nine different tissue types isolated from Setd3 +/+ and Setd3 −/− mice showed that in tissues that expressed SETD3, the majority of actin is methylated; however, this modification is not detected in any tissue obtained from SETD3-deficient mice ( Fig. 3g and Extended Data Fig. 7a-d ). Finally, quantitative profiling of serum amino acids identified depletion of 3-methyl histidine as the only abnormality in Setd3 −/− mice (Extended Data Fig. 7e ). Collectively, these results identify SETD3 as the physiological actin-His73 methyltransferase.
Actin is one of the more abundant proteins in the human proteome and His73me is a high stoichiometry event. Our data argue that SETD3 is the principal enzyme tasked with generating actin-His73me; however, it remained unclear whether actin-His73 was the only SETD3 substrate or one of many substrates. There are few known histidine-methylated proteins in addition to actin-one is myosin, which SETD3 does not methylate ( Fig. 3h ). In addition, SETD3 has no activity on histones and several other proteins ( Fig. 1c, d and Extended Data Fig. 1i ). To investigate the catalytic specificity of SETD3 in a physiological and unbiased setting, we used quantitative proteomics to compare the methylome of HeLa cells with and without SETD3 ( Fig. 3e ). Of the more than 900 methylation events detected in the analysis, including around 180histidine methylated peptides (Supplementary Table 2 ), actin-His73me was the only modification that was quantitatively altered upon SETD3 depletion ( Fig. 3i ). Together, these results indicate that the principal physiological enzymatic function of SETD3 is actin-His73 methylation.
On the basis of studies that use actin mutants, His73 and its methylation are suggested to influence actin polymerization dynamics, in part owing to its proximity to the ATP-binding site 9, 12, 14 . However, a direct side-by-side comparison of the properties of actin with and without methylation has, to our knowledge, not previously been possible. We purified actin with and without His73me (Extended Data Fig. 8a , b) from HeLa cells ( Fig. 3e ) and found that methylation promoted actin polymerization kinetics in vitro but did not affect depolymerization ( Fig. 4a and Extended Data Fig. 8c ). Moreover, the rate of ATP nucleotide exchange was faster using the unmethylated species ( Fig. 4b ). We note that actin-His73me exhibited a subtle increase in polymerization when extending off of phalloidin-actin seeds, and made little difference to the polymerization rates in response to porcine Arp2/3 complex stimulation (Extended Data Fig. 8d , e). To explore the role of His73 methylation during actin polymerization in cells, mouse embryonic fibroblasts were isolated from Setd3 +/− mice that were positive for actin-His73me and Setd3 −/− mice that lacked methylation ( Fig. 4c ). Cells that contained actin-His73me were modestly more efficient at migration than cells that were deficient in methylated actin ( Fig. 4d and Extended Data Fig. 8f ). Together, these data are consistent with a model in which SETD3 methylation of actin positively regulates actin polymerization in cells.
Although Setd3 −/− mouse embryonic fibroblasts show a defect in cell migration, Setd3 −/− mice are viable. Therefore, actin-His73me must have a specialized physiological role in vivo that is not essential for basal actin functions. The characterization of Setd3-knockout mice by the International Mouse Phenotypic Consortium scored several phenotypes, including moderate skeletal muscle myopathy, abnormal cardiac electrocardiogram and mildly decreased lean mass 13 . We did not observe gross histopathological changes in muscle tissue isolated from young adult Setd3 −/− mice (Extended Data Fig. 9a, b ). Although we did not perform a comprehensive phenotypic analysis, we observed that the litter sizes of female Setd3 −/− mice, regardless of the genotype of the sire, were significantly smaller than litters from Setd3 +/+ and Setd3 +/− females (Extended Data Fig. 9c ). To explore this observation further, we analysed parturition in Setd3 −/− or littermate control females that were all mated with wild-type males. Normal parturition was defined as birth at 19 days post-coitum (d.p.c.) and dystocia (delayed parturition) was defined as either no births (≥20 d.p.c.) or incomplete delivery with fetuses remaining in utero (≥20 d.p.c.). Dystocia is normally a rare phenotype; however, it was observed in 8 out of 9 Setd3 −/− mice, whereas normal parturition was observed for all of the control mice ( Fig. 5a ). As expected, in control mice, no fetuses were detected in utero at 20 d.p.c. (Fig. 5b ). By contrast, Setd3 −/− females typically had fetuses remaining in utero at ≥20 d.p.c. (Fig. 5b, c) .
The dystocia observed in the Setd3 −/− females is independent of the genotype of the fetus as (1) wild-type males were used as sires; (2) pups successfully born to Setd3 −/− mice were viable; and (3) Setd3 +/− females had normal parturition. Thus, the cause of dystocia is of maternal origin. Secondary maternal dystocia is unlikely as there were no obvious and consistent anatomical pelvic abnormalities present in Setd3 −/− females is the only change out of more than 900 lysine, arginine and histidine methylation events detected upon SETD3 depletion in cells. SILAC (stable isotope labelling of amino acids in cell culture)-based quantitative proteomic analysis of methylated peptides in cells with and without SETD3 using HeLa cells from e. SILAC ratios from two independent experiments are plotted in the forward direction (x axis, log 2 -transformed) and the label-swapped reverse direction (y axis, -log 2 -transformed). Forward: wild-type SETD3, light; SETD3 knockout, heavy. Reverse: wild-type SETD3, heavy; SETD3 knockout, light. SETD3-dependent methylation events are found in the top-right quadrant. For actin-His73me, no heavy peptide was found in the forward direction because of the complete loss of SETD3, so the ratio divisible by zero was plotted as infinite. An actin-His73me ratio is calculated in the reverse direction because of incomplete heavy amino acid labelling cross-contamination. Experiments were independently performed three times with similar results. For gel source data, see Supplementary Fig. 1 .
and an anatomical defect would not explain the presence of intact fetuses in utero. Thus, the dystocia is primary, either due to abnormal myometrial contractions or a defect in hormone signalling. To distinguish between these possibilities, early labour was induced in wild-type and Setd3 −/− females using oxytocin administration at 18 d.p.c. (see schematic in Fig. 5d ). Wild-type mice went into early labour and all pups were born within 24 h of treatment, whereas the dystocia of Setd3 −/− mice was refractory to oxytocin ( Fig. 5e , f). Similar results were observed with prostaglandin treatment as an independent ecbolic agent 15 (Extended Data Fig. 9d , e). These data identify a specific requirement for SETD3 in the contraction mechanism of the uterus during labour, a mechanism that fundamentally relies on proper actin behaviour 16 . As multiple, unique point mutations in actin are implicated in the aetiology of several human smooth muscle myopathies 17, 18 , we propose that there is a link between actin-His73me and uterine cell contraction in the primary dystocia of Setd3 −/− females. To test this idea, we depleted SETD3 and actin-His73me from primary human myometrial cells ( Fig. 5g ) and measured cellular contraction under normal conditions and in response to two stimulants of uterine smooth muscle contractions. Although depletion of SETD3 had only a small effect on intrinsic contractions, the absence of SETD3 significantly impeded signal-induced contractions by oxytocin and endothelin-1 ( Fig. 5h, i) . Finally, the loss of endothelin-1-induced cellular contractions upon SETD3 knockdown was rescued in the primary human myometrial cells by complementation with CRISPR-resistant wild-type SETD3, but not by the catalytically inactive SETD3(NHY) (Fig. 5j , k and Extended Data Fig. 9f ). These data suggest a specific role for actin-His73me in signal-induced contraction of smooth muscle.
Here we identify SETD3 as a metazoan protein histidine methyltransferase and the enzyme that is responsible for generating actin-His73me. SETD3 represents a SET domain family member that methylates a residue other than lysine, broadening the current framework of possible chemistries catalysed by SET domains. Our analysis reveals that histidine methylation-previously detected on only a handful of proteinsis surprisingly common, observed with a frequency that is similar to that of protein lysine di-and trimethylation 19 . Actin mutations are implicated in smooth muscle myopathies 17, 18 , including in the case of a pregnant patient who suffered from uterine muscle atony 20 . We propose that SETD3 deficiency and loss of His73me presents, similar to intrinsic actin mutations, by altering actin responsiveness to polymerization cues, which leads to defects in smooth muscle contraction. The effect of His73me on the interactions between actin and myosin is marginal (Extended Data Fig. 9g, h ), suggesting that the regulation of smooth muscle contractions is mediated by a different mechanism. Specifically, in addition to the canonical actin-myosin pathway, there is a distinct role for dynamic actin polymerization in mediating mechanical force generation of smooth muscle 21 . In summary, our work identifies a functional role for mammalian histidine methylation in regulating actin and smooth muscle contraction and suggests a broad role for this modification in the regulation of mammalian proteomes.
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Reagents. Biotinylated peptides were synthesized at the UNC High-Throughput Peptide Synthesis and Array Facility 23 . Fmoc-l-histidine amino acids with either 1-me or 3-me modifications (Sigma-Aldrich) were used in the synthesis of these peptides and synthesized peptides were purified by high-performance liquid chromatography (>92% purity). The following antibodies were used in this study: SETD3 (Abcam), pan-actin (Cytoskeleton), β-tubulin (Millipore), H3K4me2 (Cell Signaling), H3K36me2 (Cell Signaling), His73(3-me) (see below), GFP (Invitrogen), Alexa488 anti-rabbit antibody (Life Technologies), anti-rabbit and anti-mouse peroxidase-conjugated antibodies (Jackson Immunoresearch). Western blots were visualized by chemiluminescence (GE Healthcare). Anti-His73(3-me)-specific antibody generation. A peptide that corresponds to amino acids 68-78 of β-actin (KYPIEHGIVTN) with His(3-me) at position 73 was synthesized and purified by high-performance liquid chromatography (99% purity). This peptide was conjugated to KLH and used as antigen to immunize rabbits. Rabbit protocols, peptide conjugation, immunization and antiserum production were performed by Pocono Rabbit Farm & Laboratory. Antiserum was negatively selected against an unmodified actin peptide (amino acids 66-80). Final purification with was performed with an immobilized antigenic peptide to select for His73(3-me)-specific antibodies. Recombinant protein expression for in vitro reactions. SETD3 (Uniprot ID: Q86TU7) and actin were cloned into pGEX-6P-1. The MLL2 catalytic complex contained the GST-tagged catalytic SET domain of MLL2, as well as full-length, 6×His-tagged ASH2L, WDR5, DPY30 and RBBP5 proteins that were all individually expressed in bacteria and assembled in stoichiometric proportions to result in a catalytic complex 24 . Lysine methyltransferases that were used as controls were reacted with previously reported substrates [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] . Candidate substrate cDNAs were subcloned from the human ORFeome (Open Biosystems) using an LR recombination reaction (Life Technologies) into pDEST15. Mutations of all proteins were generated using Phusion site-directed mutagenesis (Thermo Scientific) according to the manufacturer's recommendations. All proteins were expressed as N-terminal GST fusions (except for non-catalytic MLL complex components) in BL21 or BL21(DE3) codon-plus bacteria. Expression was performed overnight at 16 °C in the presence of 0.1 mM IPTG. Recombinant GST fusions were purified with Glutathione Sepharose 4B (GE Healthcare) and eluted in 100 mM Tris pH 8.0, 10 mg ml −1 reduced glutathione (Sigma-Aldrich). Any cleavage of GST tags was performed with PreScission Protease (GE Healthcare) overnight at 4 °C. Recombinant 6×His-tagged proteins were purified with Ni-NTA agarose (Life Technologies) and eluted in 100 mM Tris pH 8.0 and 250 mM imidazole. Kinetics experiments and crystallography used additional purification steps as described below. Purification of SETD3 for crystallography. SETD3 was expressed as a GST-fusion protein as described above. Cleared bacterial lysates that contained the soluble GST-fused SETD3 were first loaded on a self-packed glutathione-sepharose column and eluted with buffer containing 100 mM Tris (pH 8.0), 150 mM NaCl, 5% glycerol, 0.5 mM TCEP and 20 mM reduced glutathione. The GST tag was removed by approximately 100 μg PreScission Protease (purified in-house) at 4 °C overnight. The cleaved protein solution was diluted to around 50 mM NaCl and further purified by HiTrap Q-HP (GE Healthcare) with a linear gradient from 50 mM to 500 mM NaCl; SETD3 eluted together with cleaved GST around 200-300 mM NaCl. To remove GST, fractions were loaded onto a fresh glutathione-sepharose column and the flow through was collected and concentrated to around 2 ml. SETD3 was then further purified by size-exclusion chromatography (Superdex 200, GE Healthcare) in 20 mM Tris (pH 8.0), 200 mM NaCl, 5% glycerol, 0.5 mM TCEP. All purification steps were performed at 4 °C. The chromatography experiments were conducted in a BIO-RAD NGCTM system. Cellular fractionation. Cytoplasmic cellular extracts were prepared using established protocols 37 . In brief, cells were disrupted by hypotonic lysis (25 mM KCl, 1.5 mM MgCl 2 , 10 mM HEPES-KOH pH 7.9 and protease inhibitors) and dounce homogenization. Size-exclusion chromatography (Superose 6) was performed in hypotonic lysis buffer. Ion-exchange chromatography (Sepharose Q HP) columns were equilibrated in hypotonic lysis buffer and proteins were eluted on a linear gradient from 25 to 600 mM KCl. Fractions were concentrated with centrifugal filter units (Amicon, 3,000 Da molecular weight cut-off) before being used as substrate in in vitro reactions with radiolabelled SAM. Chromatography for substrate enrichment was performed with an AKTA FPLC (GE Healthcare). In vitro methylation reactions. In vitro methyltransferase reactions were performed with 5 μg methyltransferase, 1 μg substrate, and 2 μCi 3 H-Sadenosylmethionine (American Radiolabelled Chemicals) in a buffer that contained 50 mM Tris pH 8.0, 20 mM KCl and 5 mM MgCl 2 and were incubated at 30 °C overnight. Reactions were resolved by SDS-PAGE and 3 H-methylation was visualized by autoradiography and gels were stained with Coomassie blue as a loading control. Reactions with deuterated SAM (CDN Isotopes) or normal SAM (Sigma-Aldrich) were performed with SAM at a final concentration of 80 μM.
Steady-state kinetic measurements. Human β-actin peptide (residues 66-80; TLKYPIEHGIVTNWD) was used as a substrate for SETD3. The reaction mixture contained 20 mM Tris (pH 8.0), 50 mM NaCl, 0.1 mg ml −1 BSA, 1 mM DTT and 0.18 μM SETD3. To determine the Michaelis constant (K m ) value of the peptide, the concentration of SAM was kept constant at 40 μM, whereas for the determination of the K m of SAM, the peptide concentration was kept constant at 50 μM. Reactions were carried out at room temperature for 20 min with a total volume of 20 μl, and terminated by the addition of trifluoroacetic acid to 0.1% (v/v). The activity of SETD3 was measured using a bioluminescence assay (MTase-Glo, Promega) in which the reaction by-product SAH is converted into ATP in a two-step reaction and ATP can be detected through a luciferase reaction 38 . In general, 5 μl of reaction mixture was transferred to a low-volume 384-well plate and the luminescence assay was performed according to the manufacturer's protocol. A Synergy 4 Multi-Mode Microplate Reader (BioTek) was used to measure luminescence signals. Time course of methylation for three β-actin peptides. Typically, a reaction mixture contained 20 mM Tris (pH 8.0), 50 mM NaCl, 0.1 mg ml −1 BSA, 1 mM DTT, 40 μM SAM and 50 μM peptide. In addition to the unmodified peptide, 1-methyl-His and 3-methyl-His peptides were used in the activity assay. For the unmodified peptide, 0.18 μM SETD3 was used, whereas for modified peptides, 80-fold higher amounts of SETD3 (14.4 μM) were used owing to very low activity on these peptides. For each time point, 10 μl of reaction mixture was taken and trifluoroacetic acid was added to 0.1% to stop the reaction. The luminescence assay was performed as described above. Mass spectrometry. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) was performed using an Orbitrap Elite or Fusion (Thermo Scientific) and data were analysed manually or using MaxQuant software 39 . Searches to identify peptides using MaxQuant were performed with parameters to identify methionine oxidation, N-acetylation, monomethyl lysine, dimethyl lysine, trimethyl lysine, methyl histidine, monomethyl arginine, dimethyl arginine, methyl glutamine and methyl cysteine. In vitro reactions were directly resolved by SDS-PAGE before mass spectrometry analysis was performed as described above and digested with trypsin, chymotrypsin or Glu-C (Promega). Quantitative proteomic analysis was performed with SILAC, light isotopic labels (K0R0) and heavy isotopic labels (K8R10). In the SETD3-dependent methylomics experiments, no peptides with a SILAC ratio greater than 1.5 were deemed to be SETD3-dependent methyl events. No peptides (other than actin) with at least a 1.5-fold ratio in the reverse direction and NaN ratio in the forward direction were identified at all in the forward direction. Actin His73 methylation was detected with light (wild-type cells, K0R0) labelling in the forward direction and not with heavy labelling (SETD3 knockout cells, K8R10). We thus concluded that the lack of a calculable ratio (light/heavy) in the forward direction is due to the clonal nature of the cell lines being used. We therefore plotted the forward ratio as infinite (Fig. 3i ).
Targeted quantification of actin methylation was performed by manual identification of methylated and unmethylated peptides followed by integration of the area under the curve for chromatographic peaks associated with the corresponding m/z. The percentage of methylated peptides was determined as a fraction of the sum of the total area for methylated and unmethylated species. Actin was isolated from cellular or tissue sources using DNase I affinity chromatography 40 . DNase I was immobilized on NHS-activated Sepharose FF (GE Healthcare) overnight in 100 mM HEPES pH 7.5, 150 mM NaCl and 80 mM CaCl 2 . Cells and tissues were homogenized using a buffer that contained 1 M Tris pH 8.0, 600 mM KCl, 0.5 mM MgCl 2 , 4% NP-40, 1% Tween-20, 1 mM DTT, 1 mM ATP and protease inhibitors 41 (Roche). Cleared lysates were incubated with immobilized DNase I resin overnight, washed, boiled in SDS sample buffer and purified actin was resolved by SDS-PAGE. Gels were silver-stained (Thermo Scientific) after which actin bands were excised and processed for mass spectrometry by in-gel digestion with sequencing-grade trypsin. The following sources were used for the analysis of actin methylation across evolution: S. cerevisiae, mid-log BY4741; Arabidopsis thaliana, leaf tissue; Nicotiana benthamiana, leaf tissue; Caenorhabditis elegans, mixed population; Drosophila melanogaster, larvae; Spodoptera frugiperda, Sf9 cells; Danio rerio, five days post-fertilization embryos; Xenopus laevis, egg extract; Gallus gallus, skeletal muscle; Mus musculus, brain tissue as well as uterine and skeletal muscle tissues; Homo sapiens, cell lines. Crystallography. Crystallization of the SETD3-SAH-actin peptide (residues 66-80; Genscript) complex was carried out using the hanging-drop vapourdiffusion method at 20 °C after mixing SETD3 (approximately 15 mg ml −1 ) with SAH and peptide at a molar ratio of 1:4:5. This mixture was then mixed with an equal amount of crystallization solution. Three different crystal forms were obtained. Crystals with space group P2 1 were obtained with 0.2 M ammonium acetate, 0.1 M sodium citrate tribasic dihydrate pH 5.6 and 30% (w/v) polyethylene glycol 4000. Crystals with space group P2 1 2 1 2 1 were obtained with two similar conditions, either 0.2 M ammonium sulfate or 0.2 M sodium chloride, 0.1 M Bis-Tris pH 5.5, 25% (w/v) polyethylene glycol 3350 and 0.1 M Bis-Tris pH 5.5, 25% (w/v) polyethylene glycol 3350. The first form, like the P2 1 crystal, contained Letter reSeArCH two SETD3-SAH-peptide complexes per asymmetric unit, whereas the second contained only one complex.
For X-ray diffraction data collection, single crystals were flash-frozen in liquid nitrogen by equilibrating in a cryoprotectant buffer that contained crystallization solution with 25% (v/v) ethylene glycol. All datasets were collected at the SER-CAT beamline 22ID of Advanced Photon Source at Argonne National Laboratory. Crystallographic datasets were processed with HKL2000 42 . Molecular replacement was performed with the PHENIX PHASER module 43 using the structure of human SETD3 in complex with SAM (Protein Data Bank (PDB) 3SMT) as a search model. PHENIX REFINE 44 was used for refinement with 5% randomly chosen reflections for validation by the R free value. COOT 45 was used for peptide building and model corrections between refinement rounds. Structure quality was analysed during PHENIX refinements and later validated by the PDB validation server. Molecular graphics were generated using PyMOL (Schrödinger).
We note that the high-resolution data at 1.69 Å (PDB 6MBK) were the result of merging two datasets that were collected from two different parts of the same crystal. This crystal did diffract X-rays to a higher resolution but was susceptible to radiation damage, especially in the higher resolution range. The merge resulted in 98.4% completeness in the highest resolution shell of 1.75-1.69 Å. The slightly higher R work and R free values of the structure (PDB 6MBK) might be an indication of radiation damage that could not be modelled and further refinement would not lower these R values substantially and the structure and map compared well with the quality of the other two crystal forms. Actin purification for biochemical assays. Actin was purified from wild-type HeLa cells or a clonally derived HeLa cell line in which SETD3 was knocked out. Purification was adapted from established protocols 46 . In brief, HeLa cells were resuspended in lysis buffer (10 mM Tris-HCl pH 8.0, 11.6% (w/v) sucrose, 1 mM EGTA, 1 mM ATP, 5 mM DTT and protease inhibitor cocktail) and lysed by sonication. Lysates were cleared by ultracentrifugation (100,000g, 2 h). Cleared cellular extracts were loaded onto an anion-exchange column (Sepharose Q HP, GE Healthcare) equilibrated with column buffer (10 mM Tris-HCl pH 8.0, 0.2 mM CaCl 2 , 0.5 mM ATP and 0.5 mM DTT). Actin protein was eluted on a linear gradient of column buffer containing 0 mM KCl to column buffer containing 600 mM KCl. Actin-positive fractions were polymerized with 2 mM MgCl 2 and 1 mM ATP at room temperature, and polymerized actin was pelleted at 100,000g for 2 h. F-actin was resuspended and depolymerized in 2 mM Tris pH 8.0, 0.2 mM CaCl 2 , 0.5 mM DTT and 0.2 mM ATP for ≥2 days. Residual F-actin was cleared by ultracentrifugation as described above and the protein in the supernatant was used in biochemical assays.
Pyrene-based polymerization assays were performed according to commercially available kit instructions (Cytoskeleton). Purified HeLa actin was combined in a 10:1 ratio with pyrene-labelled actin from rabbit skeletal muscle (Cytoskeleton). Polymerization was induced with 2 mM MgCl 2 , 50 mM KCl and 1 mM ATP, and monitored by fluorescence in a plate reader (excitation, 355 nm; emission, 410 nm; Biotek Cytation 3, Gen5 v.3.04.17 software). Readings were taken every 60 s with orbital shaking. Depolymerization assays were performed by diluting actin that was polymerized as described above by 250-fold in 10 mM Tris pH 8.0, 0.2 mM CaCl 2 and 1 mM ATP. Depolymerization was monitored by fluorescence similar to polymerization. Phalloidin-actin seeds were made by polymerizing monomeric actin into filaments followed by incubation of the resulting F-actin with a stoichiometric excess of phalloidin (Millipore-Sigma). F-actin was pelleted for 1 h at 100,000g. F-actin was washed and resuspended in F-buffer (10 mM Tris pH 7.5, 2 mM MgCl 2 , 50 mM KCl, 1 mM ATP and 1 mM DTT) and then sheared through a 27G needle. Seeds were allowed to recover overnight at room temperature. Polymerization with seeds was performed with 2 μM seed, 1 μM monomeric actin and 0.1 μM pyrene-actin. Polymerization with Arp2/3 complex (Cytoskeleton) and recombinant WASP VCA (the verprolin, cofilin and acidic domains of the Wiskott-Aldrich Syndrome Protein) (Cytoskeleton) were used at concentrations of 5 nM and 100 nM, respectively, with 1 μM actin and 0.1 μM pyrene-actin. Nucleotide exchange. Nucleotide exchange assays were performed as previously reported 47 . G-actin monomers were transferred into a buffer without ATP (2 mM Tris pH 7.5, 0.2 mM CaCl 2 , 1 mM DTT) by desalting column (GE Healthcare, PD spin column with G-25). 1,N 6 -ethenoadenosine-5′-O-triphosphate (ε-ATP, Axxora) was added to G-actin at a final concentration of 0.3 mM and incubated on ice for at least 2 h. Unbound ε-ATP was removed by desalting as described above. ATP exchange of ε-ATP with normal ATP (100 μM) was performed with 2 μM G-actin and monitored by fluorescence (excitation, 340 nm; emission, 410 nm) in triplicate. Cell culture. HEK293T (ATCC), HT1080 (ATCC) and H1-HeLa (ATCC) cells were cultured in Dulbecco's modified Eagle's Medium (DMEM, Life Technologies) supplemented with 10% fetal bovine serum, 2 mM l-glutamine and penicillin-streptomycin (Life Technologies). Primary uterine smooth muscle cells (ATCC) were cultured in vascular cell basal medium (ATCC) supplemented with the vascular smooth muscle growth kit (ATCC). All above cell lines were authenticated and declared mycoplasma free by ATCC. Transfections were performed with either TransIT-293 or TransIT-LT1 (Mirus) in HEK293T cells or HT1080 cells, respectively. Stable cell lines were generated using lentiviral transductions. HEK293T cells were co-transfected with the lentiviral plasmid, pCMV-Δ8.2 and pCMV-VSVg in a ratio of 9:8:1 by mass. After 48 h of transfection, target cells were transduced with 0.45-μm-filtered viral supernatants supplemented with 8 μg ml −1 polybrene. Viral concentration was performed as necessary with Lenti-X lentiviral concentration solution as per the manufacturer's recommendations (Takara). Cells were selected 24 h after medium replacement. To deplete cells of SETD3, CRISPR-Cas9 components were stably expressed in HT1080 cells using lentiCRISPRv2 (Addgene) with the following single guide (sg)RNAs: control sgRNA, 5′-CTTCGAAATGTCCGTTCGGT-3′; SETD3 sgRNA 1, 5′-TGTTACAGAATGCAGCAGTC-3′; SETD3 sgRNA 2, 5′-GTATGTGCAGATCCGGACTC-3′. SETD3 sgRNA 1 was used for reconstitution experiments and generation of the clonal H1-HeLa cell line. Cell selection was performed with 2 μg ml −1 puromycin or 100 μg ml −1 hygromycin. SETD3 cDNA cloned into pLenti CMV Hygro DEST (W117-1) (Addgene) was made CRISPR-Cas9-resistant by incorporating a synonymous mutation into the PAM sequence associated with SETD3 sgRNA 1 from CGG to CTG. Reconstitution experiments were performed by transient transfection in HT1080 cells or stable incorporation by lentivirus in primary uterine smooth muscle cells. SILAC cell culture was performed with DMEM for SILAC (Thermo Scientific), supplemented with 10% dialysed fetal bovine serum, 115 mg proline (Applichem), 50 mg lysine (light, lysine HCl (Applichem); heavy, 13 C 6 , 15 N 2 -l-lysine HCl (Silantes)) and 50 mg arginine (light, arginine HCl (Applichem); heavy, 13 C 6 , 15 N 4 -l-arginine HCl (Silantes)). Cells used for SILAC-based proteomics were cultured in SILAC medium for at least one week before analysis. Immunofluorescence imaging. H1-HeLa cells were seeded overnight onto autoclaved 12-mm circle micro cover glasses (VWR) at 50,000 cells per well in 24-well plates (Greiner Bio-One). Samples were fixed with 4% paraformaldehyde (Sigma-Aldrich) for 30 min at room temperature. Each sample was incubated with anti-GFP antibody (1:300) in immunofluorescence blocking buffer (1× phosphate-buffered saline (PBS) with 3% BSA, 1% saponin and 1% Triton X-100) overnight at 4 °C. Cells were washed thoroughly with 1× PBS and then incubated for 1 h at room temperature with Alexa488 anti-rabbit antibody (1:500) and DAPI (Insitus Biotechnologies, 1:300 dilution) in immunofluorescence blocking buffer. Washed micro cover glasses were then mounted onto microscope slides (Fisher Scientific) using Vectashield with DAPI (Vector Laboratories). Images were taken with a Zeiss LSM 700 confocal microscope and processed with Volocity software. Generation of the mouse embryonic fibroblast cell line. Embryos were collected 13.5 d.p.c. and internal organs were removed. The remaining tissues of the embryos were minced and treated with trypsin to dissociate cells for 30 min at 37 °C. Trypsinization was quenched with growth medium (DMEM containing 10% fetal bovine serum). Quenched cell suspensions were plated and allowed to grow for four days. At this point, cells were frozen or used in experiments. Genotyping of new cell lines was performed with residual embryonic tissue and confirmed by western blot analysis. Cell migration assays. Cell migration assays were performed with Radius cell migration kits (Cell Biolabs). Mouse embryonic fibroblasts (1 × 10 5 cells) were plated in 24-well migration plates and allowed to attach overnight. The Radius gel was removed according to the manufacturer's protocol. After gel removal, imaging was performed over a 24-h period with a Nikon Eclipse Ti inverted fluorescence microscope and NIS Elements (version 4.60) software. During image acquisition, the environmental conditions were kept at 5% CO 2 and 37 °C (Okolab). After the 24-h period, cells were fixed and stained with DAPI according to kit instructions. Cell migration was quantified by re-imaging migration fields and counting DAPI-stained nuclei within the boundary of the circular void left by the gel at 0 h. Migration assays were performed in triplicate. Cell contraction assays. Cellular contraction assays were performed on a collagen substrate (Cell Biolabs). In brief, 450 μl collagen mixture made with the provided 5× PBS was added to a 24-well plate and allowed to polymerize according to the manufacturer's protocol. Primary uterine smooth muscle cells (5 × 10 4 cells) were layered on top of a collagen matrix in vascular basal medium without the growth kit. Cells were allowed to attach to the collagen overnight at 37 °C. The next day, the collagen disks were released from the sides of each well. Induction of contraction was performed with 10 μM oxytocin (Tocris) or 1 μM endothelin-1 (Tocris). Contraction was monitored by imaging after 24 h of contraction. Quantification of collagen disk area was performed in ImageJ (NIH). Relative disk area was determined by normalizing to the area of disks that lacked cells. All assays were performed in triplicate. Ethics statement. Mice were housed in the Stanford mouse facility accredited by the Association for Assessment and Accreditation of Laboratory Animal Care. All experiments were approved by Stanford's Institutional Animal Care and Use Committee.
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Maintenance of mouse colonies. Husbandry is performed in accordance with the Guide for the Care and Use of Laboratory Animals, 8th edition (2010) and the 2015 revision of the Public Health Service Policy on Humane Care and Use of Laboratory Animals. Room conditions included a temperature of 23 °C, relative humidity of 30-40% and a 12:12-h light:dark cycle (lights on, 07:00). All mouse colonies are maintained under specific pathogen-free conditions in irradiated disposable individually ventilated cages (Innocage, Innovive) with irradiated, corncob bedding, irradiated food (Teklad 2918 Global 18% Protein Rodent Diet, Envigo) and ultraviolet-light-irradiated, acidified (pH 2.5-3.0), reverse-osmosis-purified bottled water (Aquavive, Innovive). The mouse colonies are monitored for viral, bacterial and parasitic pathogens using dirty-bedding sentinels that were tested quarterly and were found to be free of mouse parvovirus, minute virus of mice, mouse hepatitis virus, mouse rotavirus, Theiler's murine encephalomyelitis virus, murine norovirus, Sendai virus, mouse adenovirus 1 and 2, ectromelia virus, lymphocytic choriomeningitis virus, pneumonia virus of mice, respiratory enterovirus III, fur mites, lice and pinworms. Sample size was maximized as much as possible to gain highest confidence in the results. No randomization was necessary as only single variables changed per experiment. Blinding was not necessary as any phenotypic assessment or other measurements was performed using discrete, quantitative measurements. Mouse strains. Setd3 tm1.1(NCOM)Mfgc /Tcp C57BL/6N heterozygous mice were obtained from the Canadian Mouse Mutant Repository (CMMR). The strain was made at the Toronto Centre for Phenogenomics as part of the NorCOMM2 project using NorCOMM embryonic stem cells 48 . Progeny were genotyped using either the Setd3-McKerlie PCR assay to identify the 212-bp wild-type band (primers: Setd3 WT F1 AACCAGCAGTGCACAGAGACAAGCTG; Setd3 WT R1 AACCCAAACTCTGCCAGCCAAAGCAC) and/or a 566-bp tm1.1 band (primers: Setd3 tm1 F4 AAACTGGTGCTGCTGATAACCTGGGC; GH717 CACCGACGCCAATCACAAACAC) following instructions provided by the CMMR or the use of a commercial genotyping service (Transnetyx). For timed pregnant matings, C57BL/6N male mice were purchased from Charles River Laboratories. Male mice began breeding at 8 weeks and female mice at 6 weeks. Typically, mice no older than 6 months were used in this study. Quantification of litter size and length of gestation. Quantification of pregnancies and litters for both trio-or pair-breeding females were tabulated for Setd3 −/− , Setd3 +/− and Setd3 +/+ females. All litters that were observed (confirmed) were counted, even if pups subsequently died. To determine the number of pups per litter, litters that were lost before the pups could be counted were listed as 0 pups for that litter. The length of gestation for Setd3 −/− , Setd3 +/− and Setd3 +/+ females was determined by timed pregnant matings. Females were mated to wild-type C57BL/6N males (Charles River Laboratories). Whether the female was a virgin (primigravida) or had a previous pregnancy (multigravida) was recorded. Presence of a vaginal plug was denoted 0 d.p.c. Plugged females were moved to a separate cage and weights taken at intervals to confirm pregnancy. A few days before 19 d.p.c., the female was placed in a separate cage and provided with nesting material (Enviro-dri, Shepherd Speciality Papers) and a paper tube. Cages were checked for births twice daily (morning and afternoon) starting from 18 d.p.c. Quantifying dystocia and fetuses in utero. The day of parturition for Setd3 −/− females varied from 19 d.p.c. to ≥20 d.p.c. Normal parturition was defined as birth at 19 d.p.c. and dystocia (delayed parturition) was defined as either no births (≥20 d.p.c.) or incomplete delivery with fetuses remaining in utero (≥20 d.p.c.). To determine whether Setd3 −/− females that delivered on 19 d.p.c. still exhibited a delayed in parturition, females were euthanized on late 20 d.p.c. if they did not deliver on 19 d.p.c. (Setd3 −/− ) or 24 h after giving birth if they delivered on 19 d.p.c. (Setd3 −/− , Setd3 +/− and Setd3 +/+ ) and examined for the presence of fetuses in utero. We note that the dystocia occurred in both primigravida and multigravida Setd3 −/− females and that actin-His73me is not detected in the uterus of late-stage pregnant Setd3 −/− females (data not shown). Induction of parturition. Oxytocin (VetOne, MWI Veterinary Supply Co.) was given subcutaneously on 18 d.p.c. to induce preterm labour (dose, 0.4 U in 0.9% saline supplemented with 0.1% calcium gluconate and 0.025% dextrose, given in a total of 3 injections (once every 30 min over a period of 1.5 h) to Setd3 −/− and Setd3 +/+ timed-pregnant females. The normal day of birth for Setd3 +/+ mice of this strain is 19 d.p.c. All pups born on 18 d.p.c. were removed and euthanized. All mice quantified for fetuses in utero were euthanized at 17:00 on day 19.
A PGF2α cocktail (1 ml Lutalyse (5 mg PGF2α per ml), 1 ml 10% calcium gluconate, 0.05 ml of 50% isotonic dextrose and 8.0 ml of 0.9% sterile saline) was used to induce parturition in two Setd3 −/− females on 19 d.p.c. Females were injected subcutaneously with 1 ml of the cocktail at three time points on 19 d.p.c. (around 09:00, 12:00 and 17:00). The females were monitored for parturition and euthanized on late 20 d.p.c. at 17:00. Metabolic analysis. Amino acids were analysed as underivatized compounds by LC-MS/MS. Samples (50 μl) were deproteinized with 50 μl of 6% sulfosalicylic acid and centrifuged for 15 min at 17,000g. Supernatants were diluted with an isotopic standard mixture (Cambridge Isotope Laboratories) in 2 μM tridecafluoroheptanoic acid and then injected into the LC-MS/MS system. Samples were analysed using a clinically validated amino acid analysis method 49 . An Agilent 1200 series liquid chromatography system equipped with a Thermo Hypercarb trap column (3 μm, 4.6 mm × 50 mm) and a Waters BEH C18 analytical column (2.5 μm, 2.1 mm × 100 mm) was used to separate compounds in a trap and reverse-elute configuration. An Agilent 6460 triple quadrupole mass spectrometer was used in positive polarity electrospray ionization for detection by dynamic multiple-reaction monitoring. Mobile phase A was 0.02% perfluoroheptanoic acid and mobile phase B was acetonitrile. Standard curves were prepared by diluting amino acid standards (Wako Chemicals); for 1-methyl histidine, S-aminoethyl cystine was used as the internal standard and for 3-methyl histidine, histidine-13 C 6 15 N 3 was used as the internal standard. Agilent Masshunter B08 was used for data analysis. Muscle tissue histology. Tissues were fixed by immersion in 10% neutral-buffered formalin, processed for paraffin embedding and 5-μm thick sections were stained with haematoxylin and eosin. Myosin expression and purification. Construction, expression and purification of the wild-type recombinant human β-cardiac myosin sS1 and the hypertrophic cardiac myopathy H251N mutant 50 are described in detail elsewhere [50] [51] [52] . In brief, a truncated version of MYH7 (residues 1-808), corresponding to sS1, with a C-terminal enhanced green fluorescent protein (eGFP), was co-expressed with myosin light chain 3 (MYL3), encoding human ventricular essential light chain (ELC) and containing an N-terminal Flag tag (DYKDDDDK) and tobacco etch virus (TEV) protease site in mouse myoblast C2C12 cells using the AdEasy Vector System (Obiogene). The myosin heavy chain with its associated Flag-tagged ELC was first purified from clarified lysate with anti-Flag resin (Sigma-Aldrich). After cleaving off the Flag tag with TEV protease, the human β-cardiac sS1 was further purified using anion exchange chromatography on a 1-ml HiTrap Q HP column (GE Healthcare). Peak fractions were eluted with column buffer (10 mM imidazole pH 7.5, around 200 mM NaCl, 4 mM MgCl 2 , 1 mM DTT, 2 mM ATP and 10% sucrose) and concentrated by centrifugation in Amicon Ultra-0.5 10-kDa cut-off spin filters (EMD Millipore) before being used in assays or stored at −80 °C. In vitro motility. Experiments were conducted following previously described methods [52] [53] [54] [55] . In brief, frozen myosin proteins were first subjected to a 'deadheading' procedure to remove inactive heads. Myosin was mixed with 5-10× molar excess of unlabelled F-actin on ice for 5 min, followed by addition of 2 mM ATP for 3 min, then centrifuged at 350,000g in a TLA-100 rotor (Beckman Coulter) at 4 °C for 20 min. The supernatant was collected for use in the motility. Flow chamber was built on a nitrocellulose-coated coverslip mounted on a glass slide. Deadheaded myosin was immobilized via specific binding to the GFP antibody that non-specifically binds to the coverslip surface, followed by blocking with assay buffer (25 mM imidazole pH 7.5, 25 mM KCl, 4 mM MgCl 2 , 1 mM EGTA, 10 mM DTT and 1 mg ml −1 BSA). A final solution containing fluorescently labelled bovine cardiac F-actin, 2 mM ATP, and an oxygen-scavenging system (0.4% glucose, 0.11 mg ml −1 glucose oxidase and 0.018 mg ml −1 catalase) was subsequently flowed in before imaging on a total internal reflection fluorescence microscope (Nikon Eclipse Ti-E) equipped with a 561-nm laser (Cobolt) and a 100× oil-immersion objective (Nikon) 56 . Time-lapse movies were acquired at multiple fields of views for each experimental condition at 1 Hz sampling rate. Movies were analysed using the FAST (fast automated spud trekker) software 57 to obtain the mean velocities with 20% tolerance. All experiments were conducted at 23 °C. Actin-activated myosin ATPase activity. Purified actin was freshly cycled to F-actin by extensive (four times over 4 days) dialysis in ATPase buffer (10 mM imidazole, pH 7.5, 5 mM KCl, 3 mM MgCl 2 and 1 mM DTT) to remove any residual ATP. The monomeric concentration of F-actin was determined by measuring the absorbance of a serial dilution of the actin in 6 M guanidine hydrochloride both at 290 nm with an extinction coefficient of 26,600 M −1 cm −1 and at 280 nm with an extinction coefficient of 45,840 M −1 cm −1 in a spectrophotometer (NanoDrop). Full-length human gelsolin was added to actin at a ratio of 1:1,000 to reduce the viscosity of the actin and decrease the pipetting error at higher actin concentrations without affecting the ATPase activity. The steady-state actinactivated ATPase activities of freshly prepared human β-cardiac sS1-eGFP myosin using wild-type and knockout actin were determined using a colorimetric readout of phosphate production 58 , as described previously 52 . In this assay, reactions containing sS1 at a final concentration of 0.01 mg ml −1 , 2 mM ATP and actin at concentrations ranging from 5 to 77 μM were performed at 23 °C with shaking using a microplate spectrophotometer (Thermo Scientific Multiskan GO). The rate of sS1 activity was obtained by linear fitting of the phosphate signal as a function of time and converting to activity units using a phosphate standard. Each actin condition was performed in duplicate. The error on each data point represents the s.e.m. of the duplicates. The Michaelis-Menten equation was fitted to determine the maximal activity (k cat ) and the actin concentration at halfmaximum (apparent K m for actin). Statistics. GraphPad Prism 7.0 and KaldeidaGraph 4.5 were used for statistics.
Extended Data Fig. 4 | Methylation of the conserved actin-His73 residue is present in diverse organisms. a, Summary of actin histidine methylation on the conserved His73 residue among model organisms. Abundance of methylation is reported as a percentage of peptide that is methylated. b, Chromatograms of MH 3+ ions (m/z ± 10 p.p.m.) for methylated and unmethylated versions of the indicated peptides. The unmethylated actin peptide that was analysed for each species is shown above the corresponding chromatograms. When α-actin peptides were detected, associated chromatograms and quantification are provided on the right. The area of indicated peaks was normalized to the sum of the area between peptides (with or without methylation) and the percentage abundance is labelled. Chromatograms that quantify actin histidine methylation in human and mouse can be found in Extended Data Figs. 6, 7. N.D., not detected. Quantification represents data from two independent experiments with similar results.
Extended Data Fig. 5 | Structural details of SETD3-actin peptide interactions. a, Overall structure of SETD3 with a V-shaped cleft constructed by the SET domain (green) and an LSMT-like domain (cyan). Helices are shown as cylinders and strands as arrows. The actin peptide is shown as a stick model. b, View of the target histidine through the channel from the SAH-binding pocket. c, Omit electron density of F o -F c , contoured at 3.0σ above the mean, is shown for omitting cofactor SAH and the actin peptide used for co-crystallization. d, Details of inter-and intramolecular interactions between SETD3 (green) and actin peptide (yellow). e, Trp79 of actin bound in a hydrophobic surface pocket of SETD3. f, Thr77 and Asn78 of actin form hydrogen bonds with Asn153 and Gln254 of SETD3. g, Val76 of actin is in van der Waals contact with SETD3 residues His323 and Arg315, which in turn interacts with Glu72 of actin. h, Ile75 of actin is in van der Waals contact with main-chain C α of Asn255 and Gln256 of SETD3. i, Gly74 of actin is located in the amino end of a SETD3 helix. The imidazole ring of His73 (the substrate target) is parallel with the aromatic ring of Tyr312 of SETD3. j, SETD3 Arg315 bridges between the carboxylate oxygen of Glu72 and the main-chain carbonyl oxygen of His73 of actin. k, Ile71 of actin is accommodated in a surface hydrophobic pocket of SETD3. l, Tyr69 and Pro70 of actin interact with a stretch of SETD3 residues from Ile283 to Leu289. m, Tyr69 of actin packs against Pro258 of SETD3 and Lys68 of actin interacts with Glu290 of SETD3. n, Leu67 and Pro70 of actin form an intramolecular interaction and both interact with Ile283 and Thr284 of SETD3. o, Alignment of the amino acids from all six human actin isoforms corresponding to β-actin amino acids 66-80. Variant amino acids are highlighted in yellow. p, The cofactor (SAH) binding site includes residues Arg253, Tyr312, Asn277 and His278 of SETD3. where Fobserved and Fcalculated are the observed and calculated structure factors, respectively. Rfree was calculated using a randomly chosen subset (5%) of reflections that were not used for refinement.
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6MBK (Two complexes in P212121) and 6MBL (one complex in P212121). Source data for this study are provided as supplementary information (Fig. 4d, 5b , 5e, 5f, 5i, 5k; Extended Data Fig. 7e, 9c, 9h ). Source gel data provided for cropped images (Fig. 1a, 1d, 1e, 2a, 2c , 3a-f,g, 4c, 5g, 5j; Extended Data Fig. 1b ) is provided in Supplementary Figure 1 . Mass spectrometry data associated with Fig. 1c /Extended Data Fig. 1h and Fig. 3i are provided as a Supplementary Tables. Additional requests can be made to the corresponding authors.
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Sample size
No statistical measure was used to predetermine sample size. The dystocia phenotypic analysis resulted in an almost binary outcome leading to a strong conclusion with the sample size provided.
Data exclusions No data were excluded
Replication Experiments were replicated as indicated in the figure legends. Generally, all experiments were performed with three independent biological replicates. All results repeated during replication.
Randomization No randomization was necessary as only single variables changed per experiment
Blinding Blinding was not necessary as any phenotypic assessment or other measurements was performed using discrete, quantitative measurements
Reporting for specific materials, systems and methods 
Antibodies
Antibodies used
Primary: SETD3 (Abcam, #176582, Lot GR283420-5); Actin (Cytoskeleton, #AAN01, Lot 123); Beta-tubulin (Millipore, #05-661 clone AA2, Lot 2834905); H3K4me2 (Cell Signaling, #9725); H3K36me2 (Cell Signaling, #2901); GFP (Invitrogen, A-11122). Antiactin-H73(3-me) polyclonal antibody was made in-house. Secondary: Alexa488 anti-rabbit antibody (Life Technologies, A-11008), anti-rabbit-HRP (Jackson Immunoresearch, 711-035-152), anti-mouse-HRP (715-035-151) Validation SETD3 antibody validated by loss of detection after CRISPR/Cas9 knockout with multiple guide RNAs. Actin, beta-tubulin, and secondary antibodies were validated by the vendor across multiple cell types. Anti-actin-H73(3-me) polyclonal antibody was validated by dot blot with unmodified, H73(3-me), and H73(1-me) peptides and western blotting with cell extracts where actin methylation was quantified by mass spectrometry. H3K36me2 and H3K4me2 antibodies were validated by the vendor and independently on a peptide array containing multiple modified histone peptides.
